Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
Latest News
-
-
Multiply Labs’ biomanufacturing robot to “slash cell therapy costs”
Multiply Labs has developed a robotic biomanufacturing cluster that the company claims can reduce the cost of cell and gene…
-
Bavarian Nordic’s Vimkunya makes UK debut amid Ixchiq suspension
Bavarian Nordic has launched its chikungunya vaccine, Vimkunya, in the UK. This follows the sharp rise in travel-related disease incidences…
-
ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
-
Viking’s stock plummets on obesity pill trial results
Viking Therapeutics’ dual-targeting oral weight loss drug has disappointed investors after it showed lower efficacy than offerings from pharma giants…
-
RFK Jr’s mRNA funding halt signals “shift in US public health”
Robert F Kennedy, Jr (RFK Jr) has announced plans to cut government funding to messenger RNA (mRNA) vaccine development run…
-
US-China tensions offer new opportunity for APAC biotechs, report suggests
Investors are increasingly focused on biotech companies outside of China operating in the Asia-Pacific (APAC) market, according to a report…
-
Sandoz bolsters in-house biosimilar manufacturing with Evotec acquisition
In a bid to boost its presence in the lucrative biosimilar space, Sandoz has signed a non-binding agreement to buy…
-
GSK’s speciality medicines soar while generals drop, Q2 results reveal
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio.…
-
Apnimed sets sights on sleep apnoea pill approval following Phase III win
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on…
